InSite Vision to Report Third Quarter Financial Results on November 4, 2010

ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) announced today that it will report financial results for the third quarter ended September 30, 2010 on Thursday, November 4, 2010.

Company management will also host a conference call that day beginning at 4:30 p.m. ET/1:30 p.m. PT to provide a general business overview and discuss third quarter 2010 financial results. Investors can submit questions prior to the conference call via the company's website at www.insitevision.com through the "Information Request" tab on the Investor Relations page.

Analysts and investors can listen to the conference call by dialing (877) 407-9205 for domestic callers and (201) 689-8054 for international callers. A telephone replay will be available following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 359841.

The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing third quarter 2010 financial results will also be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance™ (besifloxacin ophthalmic suspension) 0.6%, marketed by InSite Vision’s licensee Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes ISV-502 and ISV-305 for the treatment of eye infections, and ISV-303 for pain and swelling associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.



CONTACT:

InSite Vision
Louis Drapeau, 510-747-1220
Chief Executive Officer
[email protected]
or
BCC Partners
Media inquiries
Michelle Corral, 415-794-8662

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Optical  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.